Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRESTIGE-AMI: SGLT-2 Inhibitor in Acute Myocardial Infarction
NCT04899479Phase 4Recruiting
- Sponsor
- Samsung Medical Center
- Start
- Jul 2021
- Primary completion
- Aug 2025
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in acute myocardial infarction (AMI) and heart failure (HF) (2 arms), sponsored by Samsung Medical Center. Primary endpoints: Myocardial infarct size (IS) at 6 months and Change in Left Ventricular End-Systolic Volume at 6 months. Started Jul 2021; status: recruiting.
02
Conditions
acute myocardial infarction (AMI)heart failure (HF)
Beyond the preview
Go deeper on NCT04899479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04899479.